TAS-303
TAS-303 is an orally effective selective norepinephrine transporter (NET) inhibitor. TAS-303 inhibits human NET ligand binding with a Ki of 50.9 nM, and suppresses NET-mediated norepinephrine uptake with an IC50 of 38.9 nM. TAS-303 enhances norepinephrine-induced contraction in isolated rat urethral tissues, elevates plasma norepinephrine levels in rats, and increases urethral baseline pressure and leak point pressure. TAS-303 is applicable for research related to stress urinary incontinence, norepinephrine reuptake, and lower urinary tract function.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 1449371-87-2
- Formule: C22H20D7NO3
- Masse moléculaire:360.50
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
IC50 & Target
[1]|
Human NET 50.9 nM (Ki) |
Human NET 38.9 nM (IC50) |
In Vitro
TAS-303 (3-3000 nM; 3 h) inhibits ligand binding to human NET, SERT, and DAT, with Ki values of 50.9, 1560, and 1290 nM, respectively, and exhibits selectivity for NET[1].
TAS-303 (3-3000 nM; preincubated at 25°C for 20 min) potently and selectively inhibits the uptake of [3H]norepinephrine in MDCK cells expressing human NET, with an IC50 of 38.9 nM[1].
TAS-303 (10-1000 nM; rat isolated urethral tissue) shifts the concentration-response curve of noradrenaline-induced urethral contraction to the left[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Parmacokinetics
In Vivo
TAS-303 (0.3-3 mg/kg; p.o.; single administration) dose-dependently increases the baseline urethral pressure in healthy female Sprague-Dawley rats, with a 38% increase in pressure observed at the dose of 3 mg/kg[1].
TAS-303 (0.3-3 mg/kg; p.o.; single administration) dose-dependently increases the leak point pressure in a rat model of vaginal distension-induced stress urinary incontinence, with a 26% increase observed at the dose of 3 mg/kg [1].
TAS-303 (10-100 mg/kg; p.o.; single administration) has no effect on the immobility time in the forced swimming test of healthy female Sprague-Dawley rats[1].
TAS-303 (1-10 mg/kg; p.o.; single administration) exerts no effects on cardiovascular parameters in conscious healthy dogs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley (female, 10 weeks of age)[1]
-
Dosage:3 mg/kg
-
Administration:p.o.; once daily for 7 days
-
Result:Increased plasma norepinephrine levels significantly compared to vehicle-treated rats.
Produced no differences in plasma epinephrine, dopamine, or serotonin levels compared to vehicle-treated rats.
-
Animal Model:Sprague-Dawley (female, 11 weeks of age)[1]
-
Dosage:0.3 mg/kg; 1 mg/kg; 3 mg/kg
-
Administration:p.o.; single dose
-
Result:Produced a dose-dependent increase in urethral baseline pressure.
Increased urethral pressure significantly at doses of 1 mg/kg and 3 mg/kg compared to vehicle.
Increased urethral baseline pressure by 38% at the 3 mg/kg dose.
-
Animal Model:Sprague-Dawley (female, 11 weeks of age, stress urinary incontinence induced by vaginal distention)[1]
-
Dosage:0.3 mg/kg; 1 mg/kg; 3 mg/kg
-
Administration:p.o.; single dose
-
Result:Produced a dose-dependent increase in leak point pressure (LPP).
Increased LPP significantly at doses of 1 mg/kg and 3 mg/kg compared to vehicle.
Increased LPP by 26% at the 3 mg/kg dose.
-
Animal Model:Sprague-Dawley (female, 11 weeks of age)[1]
-
Dosage:10 mg/kg; 30 mg/kg; 100 mg/kg
-
Administration:p.o.; single dose
-
Result:Produced no significant change in immobility time compared to vehicle-treated rats at all tested doses.
-
Animal Model:Conscious dogs[1]
-
Dosage:1 mg/kg; 3 mg/kg; 10 mg/kg
-
Administration:p.o.; single dose
-
Result:Produced no significant changes in systolic blood pressure, diastolic blood pressure, mean blood pressure, or heart rate compared to vehicle-treated dogs at all tested doses.
Essai clinique
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Application
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
CAS No. 1449371-87-2
-
Unlabeled CAS 108640-65-9
-
Masse moléculaire 360.50
-
Formule C22H20D7NO3
-
SMILES
C(C(OC1CCNCC1)=O)(OC(C(C([2H])([2H])[2H])([2H])[2H])([2H])[2H])(C2=CC=CC=C2)C3=CC=CC=C3
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
TAS-303 Related Classifications
HY-167227S Related Classifications
Powered by Bioz